2024年4月6日～2024年4月12日の間に収集した論文情報を追加しました。
1. Adverse events following Measles-Mumps-Rubella and varicella immunization: A safety profile analysis and comparison of different vaccination schedules based on the Italian Pharmacovigilance Network in the Veneto Region.
MMRVとMMR-Vワクチンの安全性を比較
対象DB：FAERS,VAERS
2. Antibiotics-associated pseudomembranous colitis: a disproportionality analysis of the US food and drug administration adverse event reporting system (FAERS) database.
FAERSデータを用いたPMCと抗生物質の関連性の研究
対象DB：FAERS
3. Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine - Oregon, June 2021-December 2022.
COVID-19ワクチン接種と若者の突然死の関連性についての研究
対象DB：FAERS,VAERS
4. Long-term safety of lanthanum carbonate in the real word: a 19-year disproportionality analysis from the FDA Adverse Event Reporting System.
FAERSデータを用いたランタノカーボネートの長期安全性評価
対象DB：FAERS
5. A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions.
FAERSデータを用いた併用療法における有害事象のパターン分析
対象DB：FAERS
6. Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects.
システム薬理学データを活用したベイズフレームワークによる新規の薬物相互作用シグナル検出手法
対象DB：FAERS
7. Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database.
FDAのFAERSデータを用いたトリアゾール系抗真菌薬の心疾患に関連する有害事象の分析
対象DB：FAERS
8. Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records.
FAERSデータを活用した新たな薬剤相互作用の信頼性評価手法
対象DB：FAERS
9. Polymyalgia Rheumatica After COVID-19 Vaccination: Data from the EudraVigilance Database.
COVID-19ワクチン後の多発性筋痛症
対象DB：EudraVigilance
10. COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance.
COVID-19ワクチン接種後の月経不順報告は、メディアの影響を受けて増加した可能性
対象DB：EudraVigilance
11. Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults.
ADHD治療におけるアンフェタミン使用が精神病症状の報告リスクを高める可能性
対象DB：VigiBase
12. Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case/non-case analysis.
COVID-19ワクチンの副作用報告が自動シグナル検出に影響を与える可能性
対象DB：VigiBase
13. A case of hypophosphatemia and elevated intact fibroblast growth factor 23 levels after short-term saccharated ferric oxide administration in a young woman and database analysis of adverse drug reactions in Japan.
SFO投与後の早期に低リン血症が報告され、定期的なモニタリングが重要
対象DB：JADER
14. Noninvasive Positive Airway Pressure Management for Post-extubation Support in Preterm Infants: Observational Cohort Study with Overlap Weighting Analysis.
早産児の経管後支援において、NCPAP/NIPPVがHFNCより有効
対象DB：DPC
15. Use of Japanese Herbal Kampo Medicine in Patients With Acute Cardiovascular Disease - A 12-Year Nationwide Cohort Analysis.
急性心血管疾患患者における漢方薬の使用が増加
対象DB：DPC
16. Association of Inflammatory Bowel Disease with Incident Immunoglobulin A Nephropathy.
大規模エピデミオロジー研究により、炎症性腸疾患とIgA腎症の関連が示唆
対象DB：JMDC
17. Nationwide epidemiology and health resource use among children with COVID-19 in Japan.
日本の小児医療システムのCOVID-19対応の変化を分析
対象DB：DeSC,JMDC
18. Epidemiology of Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection in Japanese Children, 2011-2017.
日本の幼児におけるRSV関連のエピデミオロジーと医療リソース利用の分析
対象DB：JMDC
19. Trends in hip preservation surgery in Japan from 2014 to 2019 with a focus on hip arthroscopic surgery.
日本における股関節保存手術の傾向調査
対象DB：NDB
20. Epidemiology of patients with lymphangioleiomyomatosis: A descriptive study using the national database of health insurance claims and specific health checkups of Japan.
リンパ管筋脂肪腫の発生率と有病率の推定。治療や死亡率の変化も調査
対象DB：NDB
21. Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain.
日本のがん疼痛患者における便秘治療の実際のパターン
対象DB：MDV
22. Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study.
日本における実際のRA治療の傾向。TNFiが主な初期療法
対象DB：MDV
23. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.
日本の乳がん患者におけるAI処方と骨折リスクの関連性は不明
対象DB：MDV
24. Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) using a Japanese claims database.
日本の一般病院におけるCTDおよびCTD-PAH患者の診断と治療を調査
対象DB：MDV
25. The impact of the UK COVID-19 lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: a population-based cohort study.
COVID-19パンデミックががんスクリーニングと診断に大きな影響を与えた
対象DB：CPRD
26. A Harmonised Approach to Curating Research-Ready Datasets for Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Interstitial Lung Disease (ILD) in England, Wales and Scotland Using Clinical Practice Research Datalink (CPRD), Secure Anonymised Information Linkage (SAIL) Databank and DataLoch.
EHRデータを用いた呼吸器疾患の研究
対象DB：CPRD
27. Role of sociodemographic characteristics on the progression of multimorbidity over time: a longitudinal approach using the Clinical Practice Research Datalink of England.
社会人口特性が多疾患状態の経過に与える影響
対象DB：CPRD
28. Cross-reactivity among and between macrolides, lincosamides, and streptogramins: Study on the French pharmacovigilance database.
MLS抗生物質間の過敏症の交差反応可能性
対象DB：FPVD